The aberrant behavior of cancer reflects upregulation of certain oncogenic signaling pathways that promote proliferation, inhibit apoptosis, and enable the cancer to spread and evoke angiogenesis. Theoretically, it should be feasible to decrease the activity of these pathways-or increase the activity of pathways that oppose them-with noncytotoxic agents. Since multiple pathways are dysfunctional in most cancers, and cancers accumulate new oncogenic mutations as they progress, the greatest and most durable therapeutic benefit will likely be achieved with combination regimens that address several targets. Thus, a multifocal signal modulation therapy (MSMT) of cancer is proposed. This concept has already been documented by researchers who have shown that certain combinations of signal modulators-of limited utility when administered individually-can achieve dramatic suppression of tumor growth in rodent xenograft models. The present essay attempts to guide development of MSMTs for prostate cancer. Androgen ablation is a signalmodulating measure already in standard use in the management of delocalized prostate cancer. The additional molecular targets considered here include the type 1 insulin-like growth factor receptor, the epidermal growth factor receptor, mammalian target of rapamycin, NF-κB, hypoxia-inducible factor-1α, hsp90, cyclooxygenase-2, protein kinase A type I, vascular endothelial growth factor, 5-lipoxygenase, 12-lipoxygenase, angiotensin II receptor type 1, bradykinin receptor type 1, c-Src, interleukin-6, ras, MDM2, bcl-2/bcl-xL, vitamin D receptor, estrogen receptor-β, and PPAR-. Various nutrients and phytochemicals suspected to have potential utility in prostate cancer prevention and therapy, but whose key molecular targets are still unknown, might reasonably be incorporated into MSMTs for prostate cancer; these include lycopene, selenium, green tea polyphenols, genistein, and silibinin. MSMTs can be developed systematically by testing various combinations of signal-modulating agents, in concentrations that can feasibly be achieved and maintained clinically, on human prostate cancer cell lines; combinations that appear promising can then be tested in xenograft models and, ultimately, in the clinic. Some signal modulators can increase response to cytotoxic drugs by upregulating effectors of apoptosis. When MSMTs fail to raise the spontaneous apoptosis rate sufficiently to achieve tumor stasis or regression, incorporation of appropriate cy-totoxic agents into the regimen may improve the clinical outcome.
Signal Modulation Therapy for Cancer Control
Malignant cells are characterized by the upregulation or constitutive activation of multiple signaling pathways that promote proliferation, inhibit apoptosis, and enable the cells to invade and migrate through tissues while evoking angiogenesis. Downregulation or loss of proteins and pathways that oppose these behaviors is also commonly seen. Theoretically, once these upregulated oncogenic pathways have been identified in a cancer, it should prove feasible to achieve partial inhibition of these pathways with tolerable doses of several noncytotoxic pharmaceutical agents, thereby suppressing the malignant behavior of the cancer and tipping the balance of proliferation/apoptosis toward the latter; in some favorable cases, tumor stasis or even regression might be achievable. The likelihood that any single drug would have a "magic bullet"-like impact on a cancer is lessened by the fact that over the course of their evolution, cancers acquire multiple oncogenic mutations that are often functionally redundant; thus, inhibiting any single upregulated pathway may have only a modest impact on tumor behavior. Even when a single drug does initially have striking activity (eg, androgen antagonists in early prostate cancer), it is common for cells in the regressing cancer to acquire additional mutations that render them resistant to the functional impact of the original therapy, leading to tumor recurrence. Thus, a plan of attack targeting multiple signaling pathways that are prone to upregulation in a given type of cancer seems to offer the best prospects for achieving long-term control of that cancer.
Although these considerations seem virtually selfevident, there appear to be few studies or reviews in the biomedical literature that enunciate or illustrate this strategy. Most studies focus on a single pharmaceutical agent-drug, nutrient, or phytochemicalthat addresses a single target. Such studies are essential, as it is necessary to define dosage schedules that can achieve meaningful inhibition (or activation) of the targeted pathway without entailing unacceptable side effects. Yet clinical studies that evaluate the efficacy of a single agent are apt to achieve rather disappointing results-in most cases, retardations of tumor growth and spread that are inherently difficult to verify, rather than the objective remissions or long-term tumor stasis that are the traditional goals of cytotoxic cancer therapy. This is only to be expected and should not give rise to discouragement. The clinical payoff will come when it becomes feasible to administer several different agents simultaneously, targeting multiple oncogenic pathways in the cancer.
The best illustration of this principle of which I am aware has been provided by Tortora and colleagues. 1 These workers tested the efficacy of an inhibitor of the epidermal growth factor receptor (Iressa), a cox-2 inhibitor, and an orally administrable antisense agent targeting protein kinase A type I, administered separately or in combination, against human breast and colon cancer cells in vitro as well as human colon cancer xenografts implanted in nude mice. In the cell culture studies, they found that low concentrations of the agents that, given singly, would suppress cell colony growth rate by no more than 15% to 20% could achieve a virtually complete suppression of colony growth when all 3 agents were administered simultaneously. Analogous findings were reported in the xenograft model. The cox-2 inhibitor did not retard growth of the tumors, and no more than a 15-day delay in tumor growth was achieved with either Iressa or the antisense agent administered singly. In contrast, the triple therapy achieved a profound suppression of tumor growth, with 60% of the animals having no histological evidence of cancer 5 weeks after therapy had been terminated. In tumor biopsies obtained 32 days after tumor transplantation, the triple therapy was associated with an 80% reduction in microvessel density and an absence of detectible vascular endothelial growth factor (VEGF). The therapy appeared to be well tolerated, as no weight loss or other signs of toxicity were noted.
It is worthwhile to quote the concluding paragraph of this insightful article in full:
There is growing consensus that the blockade of key mitogenic and angiogenic molecules may be a successful strategy for both chemoprevention and longterm control of cancer. Agents suitable for these purposes should have mild and differing toxicity patterns and simple administration routes. In agreement with this approach, we have shown that using oral administration of different noncytotoxic selective agents targeting molecules involved in mitogenic signaling and angiogenesis, it is possible to achieve an antitumor and antiangiogenic effect. Because all of the agents used in our study are under clinical development, we believe that this study provides a strong rationale to translate this feasible therapeutic strategy into a clinical setting. 1(p1571) The strategy of treating cancer by addressing key signaling pathways with noncytotoxic agents might reasonably be called "signal modulation therapy." The strategy of targeting several pathways simultaneously to achieve additive or synergistic efficacy could then be described as multifocal signal modulation therapy (MSMT).
Focus on Prostate Cancer
The intent of this article is to provide a concise review of metabolic pathways in prostate cancer whose upregulation (or downregulation) commonly promotes malignant behavior and that thus might be rationally targeted in multifocal signal modulation therapies of the sort envisioned above. Pharmaceutical agents-or lifestyles-that might feasibly be used to address these pathways are also considered.
Androgen-ablation strategies-while they clearly can be categorized as signal modulation therapieswill not be discussed here, as the utility of this approach, as well as its limitations, are already well established. When local control of prostate cancer fails, androgen antagonism remains the standard therapy. Unfortunately, even though most prostate cancers respond initially, selection for androgen-independent cells almost always leads to cancer recurrence; amplifications or mutations of the androgen receptor gene enable the receptor to be activated by nonandrogenic steroids and/or growth factors, while increased expression of various androgen receptor coactivators can promote adequate androgen receptor activity in a low androgen environment. 2 Recurrent prostate cancers that have achieved androgen independence are notoriously difficult to treat; cytotoxic therapies, if helpful at all, usually provide no more than palliative benefit. Thus, a new approach to the management of prostate cancers that have spread beyond the prostate and achieved androgen independence is desperately needed.
It should be noted that some of the better tolerated strategies envisioned below might reasonably be used in early-stage prostate cancer (the "watchful waiting period") or for primary prevention of this disease.
Insulin-like Growth Factor (IGF) Receptor-Type 1
Excessive activation of tyrosine kinase growth factor receptors, by stimulating the PI3K-Akt-mTOR-p70S6k and Ras-Erk1/2 pathways, works in a variety of complementary ways to promote proliferation, inhibit apoptosis, boost angiogenic capacity, and stimulate migration/invasion. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Furthermore, in prostate cancers that have evolved to androgen independence, growth factor receptors may have the remarkable ability to activate androgen receptors in the absence of androgens. 17 The type 1 IGF receptor (IGFR1) and the receptor for epidermal growth factor (EGFR) are known to play key roles in the evolution of prostate cancer. IGFR1 is now drawing particular attention in light of prospective epidemiological evidence that relatively high serum levels of IGF-I, and relatively low serum levels of its functional antagonist IGFBP-3, are associated with increased risk for advanced prostate cancer. 18, 19 Recent studies indicate that expression of IGFR1 in primary prostate cancers tends to be upregulated as compared with benign prostate epithelium. [20] [21] [22] [23] [24] High expression of this receptor tends to be maintained in metastastic lesions, although a subset of these lesions is characterized by a decrease in IGFR1 expression coupled with a loss of phosphatase and tensin homolog (PTEN) activity; presumably, the chronic upregulation of PI3K-Akt-mTOR signaling stemming from the loss of PTEN can compensate for a reduction in IGF signaling. 22, 25 Prostate cancers commonly produce IGF-II (rather than IGF-I), giving rise to an autocrine stimulation loop that helps to sustain growth even when malignant prostate cells are cultured in serumfree medium. 23, [26] [27] [28] [29] [30] Conversely, antisense suppression of IGFR1 expression slows proliferation and boosts apoptosis in cultured prostate cancer cells. 20, 24 IGF-II production is typically higher in advanced metastatic lesions and high Gleason score cancers, as opposed to primary cancers and those with low Gleason scores. 23, [28] [29] [30] Benign prostate epithelium, as well as prostate cancers, produce the full range of IGF binding proteins, excepting IGFBP-1. 27, 29 Normal epithelium, however, produces the IGFBP-1-related protein, the expression of which is usually lost in cancers; this protein is induced by IGF-I in healthy epithelium and thus appears to act as a feedback mechanism for controlling prostate growth. 31, 32 In advanced prostate cancers, IGFBP-2 production is usually upregulated, whereas IGFBP-3 is downregulated. 28, 33, 34 Remarkably, IGFBP-2, which suppresses IGF-driven growth in healthy prostate epithelium, acts to accelerate growth in prostate cancer cells; the mechanism of this latter effect is obscure. 33, 34 Systemic levels of IGFBP-2 are usually elevated in advanced prostate cancer and tend to correlate with prostate-specific antigen (PSA) levels and cancer aggressiveness. 28 The downregulation of IGFBP-3 in prostate cancers is also of functional significance; not only does this protein oppose IGF-driven growth by binding IGFs, but it also exerts a direct growth-inhibitory effect, likely by activating transforming growth factor (TGF)-β receptors. [35] [36] [37] [38] Although prostate cancers do not produce IGFBP-1, exogenous IGFBP-1, which has high affinity for both IGF-I and IGF-II, suppresses the growth of prostate cancer cells in vitro by intervening in the IGF-II/IGFR1 autocrine loop. 26 Although most prostate cancers generate their own IGF-II, systemic IGFs have the potential to contribute to IGFR1 activation in prostate cancers. Conversely, serum IGFBP-1 and IGFBP-3 have the potential to inhibit prostate cancer growth. These considerations are of importance in light of the fact that lifestyle measures can influence hepatic production of both IGF-I and IGFBP-1. Barnard and colleagues have recently demonstrated that a very-low-fat whole-food diet, coupled with daily walking exercise-the classical "Pritikin regimen"-can markedly influence these parameters. 39 In 14 male volunteers participating in the Pritikin regimen for 11 days, serum IGF-I fell by an average of 20%, whereas IGFBP-1 increased by 53%. In 8 subjects of comparable age who had engaged in this program for an average of 14 years, IGF-I was 55% lower and IGFBP-1 150% higher relative to initial values in the first group. The regimen did not influence serum IGFBP-3 in either group. The researchers then assessed the ability of pre-and postregimen serum from the experimental group, as well as serum from the 8 "veteran" subjects, to support the growth of androgen-sensitive LNCaP human prostate cancer cells in vitro. As compared to cells incubated with preregimen serum, those grown with postregimen and veteran serum experienced 30% and 44% reductions in growth rate, respectively. Moreover, apoptosis was markedly upregulated in cells grown with the veteran serum. Adding IGF-I to the postregimen serum reversed the favorable effects of this serum on LNCaP proliferation and apoptosis; conversely, adding IGFBP-1 to the preregimen serum suppressed proliferation and boosted apoptosis. 40 In rodents, dietary protein intakes that are low in quantity and/or quality downregulate hepatic IGF-I production while upregulating that of IGFBP-1. [41] [42] [43] Allen and colleagues have reported that, as compared to omnivores or ovolactovegetarians, serum IGF-I is about 13% lower in vegans, whereas IGFBP-1 averaged 40% higher. 44 Since the fat intake of the vegans was about 30% of calories, these findings could not be attributed to the fat restriction that is crucial to the Pritikin regimen but rather reflected avoidance of animal protein and possibly saturated fat. The merit of a very-low-fat (10% fat calories) intake in this regard presumably reflects the insulin-sensitizing impact of such diets on skeletal muscle [45] [46] [47] ; the resulting downregulation of insulin secretion would be expected to have a direct influence on hepatic production of both IGF-I and IGFBP-1. 48, 49 Conflating the findings of the Barnard and Allen studies, it is reasonable to suggest that a very-low-fat, whole-food vegan diet, coupled with regular aerobic training, would be expected to downregulate the IGF-I activity of serum, thus aiding prevention and control of IGF-responsive prostate cancers. Indeed, Ornish is in the process of assessing the efficacy of such a regimen (to which he adds stress-reduction techniques) in patients with early-stage prostate cancer; preliminary findings indicate that PSA values tend to fall modestly in patients embarking on this regimen. 50 These findings may be highly germane to the very low rates of prostate cancer mortality enjoyed by rural Asian and African societies as long as they adhere to their traditional low-fat quasi-vegan diets. 51, 52 Drug-mediated reduction of hepatic IGF-I production may also be feasible. In women, the recently approved selective estrogen response modulator raloxifene is reported to decrease serum levels of IGF-I while increasing those of IGFBP-3. [53] [54] [55] [56] The impact of raloxifene on systemic IGF-I activity in men has received little study, but in 8 acromegalic men, 60 mg raloxifene twice daily was associated with an average reduction of 16% in serum IGF-I; since growth hormone levels did not decrease, this effect presumably reflects decreased hepatic responsiveness to GH. 57 Moreover, there is evidence that raloxifene may have a direct impact on prostate cancers; in vitro, raloxifene markedly enhanced apoptosis in androgen-dependent (LNCaP) as well as androgen-independent (PC-3, PC-3M, DU145) prostate cancer cell lines. 58, 59 The mechanism of this latter effect remains obscure but might reflect interaction with β-type estrogen receptors expressed in many prostate cancers. 60
Epidermal Growth Factor (EGFR)
Most human prostate cancers express the EGFR (erbB1/HER-1) and show a proliferative response to the range of ligands for this receptor, including EGF, tumor necrosis factor (TNF)-α, amphiregulin, and heparin-binding EGF.
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Furthermore, most advanced, androgen-independent prostate cancers express TGF-α, giving rise to an autocrine loop that promotes growth, survival, and migration. 62, 63, 65, 69, 70 Some, though not all, studies indicate that in androgendependent tumors, androgens increase the expression of EGFR 67, [71] [72] [73] [74] ; however, the growth-promoting effects of androgens may not be mediated solely by EGFR. EGFR expression in androgen-independent prostate cancers is usually higher than in androgendependent cancers, suggestive of a compensatory upregulation. High-level expression of EGFR has been associated with poor clinical prognosis. 75 EGFR may play a central coordinating role in the regulation of prostate cancer mitosis that is not yet understood. Thus, the ability of either IGF-I or protein kinase A to activate Erk2 in the androgen-insensitive DU145 cell line is abrogated by concurrent inhibition of EGFR. 76 This receptor also seems to play a role in the transmission of promitotic signals generated by angiotensin II, at least in breast cancer. 77 Pharmaceuticals that target EGFR include antibodies directed against the receptor ectodomain (C-225/ Erbitux) and small molecules that are receptorspecific tyrosine kinase inhibitors, most notably ZD1839 (Iressa).
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These have already achieved clinical approval for treatment of colorectal cancer and non-small-cell lung cancer, respectively. Iressa is of particular interest for long-term therapy, as it is orally administrable and reasonably well tolerated in clinical doses (controllable diarrhea being the most common side effect). A recent study shows that Iressa inhibited EGF-stimulated proliferation in a wide range of established prostate cancer cell lines as well as in primary cell cultures from prostate tumors; the concentration that inhibited EGF-stimulated proliferation by 50% was usually less than 1 µM. 66 The impact of Iressa on cell proliferation in the absence of added EGF was much more modest, suggesting that the TGF-α autocrine loop usually does not have a potent effect, at least in vitro. In vivo, C-225 administration has been shown to slow the progression of androgen-independent human prostate cancers DU145 and PC-3 implanted in nude mice. 75 Mimeault and colleagues have reported that inhibition of protein kinase A activity (with RP-cAMPs) synergizes with EGFR inhibition in suppressing EGF-or serum-driven proliferation in several human prostate cancer cell lines in vitro. 81 These findings are reminiscent of the work of Tortora cited above. Conversely, the protein kinase A (PKA) activator forskolin has been reported to potentiate the activating impact of EGF on Erk2, for reasons that remain unclear. 76 Agents that downregulate EGFR expression might have some role in prevention or therapy of prostate cancer. In the transgenic adenocarcinoma of mouse prostate model, dietary genistein downregulates prostate expression of EGFR. 82 Whether this finding has any relevance to humans is not clear, although recent clinical studies with supplemental genistein suggest that this agent may somehow slow the increase of PSA in early prostate cancer. 83, 84 Another intriguing recent study demonstrates that anandamide, acting via cannabinoid CB(1) receptors, suppresses expression of EGFR by several human prostate cancer cell lines. 85 Of related interest is a report that tetrahydrocannabinol induces apoptosis dose dependently in PC-3 cell cultures. 86 Various phytochemicals, including curcumin, grape seed extract, silibinin, and resveratrol, have been reported to block either the activation or downstream effects of EGFR in human prostate cancer cell lines in vitro. [87] [88] [89] [90] Unfortunately, the concentrations of these agents used in these studies were far beyond those that can be achieved and maintained by oral administration in humans; thus, these results are of dubious clinical relevance.
Mammalian Target of Rapamycin
The kinase mammalian target of rapamycin (mTOR) is a branch point at which the PI3K-Akt signaling pathway diverges, phosphorylating 4E-BP1 and activating p70S6 kinase. These actions upregulate protein synthesis, supporting the cell growth required prior to mitosis, while selectively stimulating the translation of proteins that support cell cycle progression from G1 to S phase (including cyclin D1), survival, and angiogenesis (notably HIF-1α, a transcription factor that promotes expression of VEGF). 91, 92 p70S6 kinase also suppresses apoptosis by inhibitory phosphorylation of BAD. 5 mTOR may be the most proximal point at which the PI3K-Akt signaling pathway can be inhibited without compromising insulin function.
mTOR is susceptible to inhibition by the natural product rapamycin (also known as sirolimus), derived from a strain of Streptomyces discovered on Easter Island. 93, 94 The properties of rapamycin were explored when this agent proved to have immunosuppressive and cancer-retardant activity in screening studies. Rapamycin and certain derivatives thereof-some of which are orally administrable-are currently in use for prevention of graft rejection; however, their clini-cal utility in cancer therapy is also being explored. 91 Rapamycin is relatively well tolerated for an immunosuppressive agent: it does not induce nausea and vomiting, and in standard clinical doses, it does not promote opportunistic infections. Skin toxicity-small papules and folliculitis-may be the most common side effect.
The impact of rapamycin on prostate cancer has so far received little attention. This agent has been shown to inhibit the growth of LNCaP and PC-3 human prostate cancer cell lines in vitro (in concentrations less than 100 nM 95 ) and, in nude mice, to reverse the resistance of PC-3 to doxorubicin. 96 In other types of cancer, cells deficient in the PTEN suppressor gene (a phosphatase that reverses the impact of PI3K on phospholipids) are especially sensitive to the cell cycleretardant impact of rapamycin, reflecting the fact that mTOR is highly active under these circumstances; since most prostate cancers have lost 1 copy of the PTEN gene, and many advanced cancers have lost both, it is reasonable to predict that a high proportion of human prostate cancers will be rapamycin responsive. [97] [98] [99] 
Nuclear Factor-κB (NF-κB)
Constitutive activation of the transcription factor NF-κB has been observed in a high proportion of androgen-independent prostate cancers. [100] [101] [102] Presumably, the ability of NF-κB to promote transcription of the prominent antiapoptotic protein Bcl-2 103 aids the survival of cells that otherwise would be at risk owing to loss of androgen activity. This constitutive activation reflects increased activity of the IκB kinase (IKK) complex, but why IKK is activated remains unclear. 102 A report that dominant negative NF-κB-inducing kinase (NIK) and tyrosine kinase inhibitors suppress the constitutively elevated NF-κB activity in various prostate cancer cell lines suggests that NIK, possibly downstream from a tyrosine kinase, may mediate the constitutive activation of IKK. 104 Other factors suggested to play a role in the constitutive activation of NF-κB in prostate cancer include 12-(S)-HETE, Id-1, bombesin, and RhoA. [105] [106] [107] [108] In addition to suppressing apoptosis, NF-κB promotes malignant behavior in other ways: stimulating transcription of cell cycle progression factors (c-myc, cyclin D1), proteolytic enzymes (MMP-9, uPA), and angiogenic factors (VEGF, IL-8). 102, 109 Thus, it is not surprising that nuclear localization of NF-κB in prostate cancer biopsies has been shown to correlate with poor clinical prognosis. 110 A bewildering array of natural products, some of which have putative chemopreventive activity, are reported to inhibit constitutive and/or stimulated NF-κB activity in human prostate cancer cell lines in vitro: apigenin, [111] [112] [113] epigallocatechin-3-gallate, [114] [115] [116] curcumin, 117, 118 inositol hexaphosphate, 119 PC-SPES, 120 selenium, 121 zinc, 122 genistein, 123, 124 silibinin, 125 and indole-3carbinol. 126 Few if any of these studies made an effort to use concentrations of the agent tested that could feasibly be achieved clinically via oral administration; thus, it is unclear whether any of these observations are clinically relevant. (Although the selenium study claims to use a concentration of selenium comparable to serum levels, this ignores the fact that the large majority of serum selenium is incorporated in proteinbound selenoamino acids that have no immediate metabolic availability.) Silibinin, which can suppress NF-κB activity in DU145 cells in a concentration as low as 10 µM 125 -an effect reflecting direct inhibition of IKKα activity-may merit further examination in this regard since oral silibinin appears to have therapeutic efficacy in human liver disorders 127 and can slow the growth of DU145 xenografts in nude mice. 128, 129 Since the transcriptional activity of NF-κB hinges on proteasomal degradation of the inhibitory protein IκB, proteasome inhibitors can be used to suppress NF-κB activity. Thus, the proteasome inhibitor PS-341, now being developed as a cancer drug, has potential for treatment of prostate cancer and has been shown to induce growth arrest and apoptosis in LNCaP cells. 130 (Ironically, this effect likely reflects something other than NF-κB suppression, inasmuch as the NF-κB activity of LNCaP cells, an androgen-sensitive tumor, is said to be quite low.) Of related interest is a report that in a concentration of 10 µM, the protease inhibitor AIDS drug saquinavir inhibits proteasome activity in a range of human prostate cancer cell lines in vitro, an effect associated with increased apoptosis. 131 PS-341 is a boronic acid dipeptide with serine protease inhibitory activity. 132 Boric acid per se can act as a serine protease inhibitor. 133 It has recently been reported that relatively modest dietary intakes of boric acid (1.7-9.0 mgB/kg/d) decrease the growth of LNCaP in nude mice and markedly decrease the expression of PSA by the tumor. 134 The latter observation was also made in the study with PS-341. 130 Could supranutritional doses of boric acid have proteasomeinhibitory activity? The impact of boron on other prostate cancer cell lines should be studied.
Copper depletion, using the well-tolerated coppersequestering drug tetrathiomolybdate (TM), is now being studied as an angiostatic treatment for cancer. 135 There is recent evidence that the angiostatic impact of copper depletion is primarily attributable to suppression of NF-κB activity in cancer cells and a consequent downregulation of tumor expression of various angiogenic factors. 136, 137 Thus, copper depletion markedly inhibited the growth of SUM149 human breast car-cinoma in nude mice but did not inhibit the (much slower) growth of the same cancer cells that had been transfected with a dominant negative IκB before transplantation. Preliminary copper depletion with TM was found to decrease subsequent tumor growth of Dunning rat prostate cancer by more than 50%. 138 It should be noted that TM, though difficult to obtain, is currently available as it is now the preferred agent for management of Wilson's disease. Theoretically, highdose zinc could be used to achieve significant copper depletion, 139 and a previously cited report regarding a downregulatory impact of zinc on NF-κB activation in vitro is of some interest in this regard. 122 Moreover, zinc administered by osmotic pump has been shown to suppress growth of PC-3 cells in nude mice. 140, 141 Why copper depletion should influence NF-κB activation remains mysterious, as the enzymes involved in activation of this transcription factor are not known to be copper dependent.
Hypoxia-Inducible Factor-1α (HIF-1α)
HIF-1α, like NF-κB, is a transcription factor that plays a key role in promotion of tumor angiogenesis. As its name implies, its activity is evoked by hypoxia, owing to the fact that its stability is substantially enhanced under hypoxic conditions. In cells that are well oxygenated, this protein has a short half-life; oxygendependent prolyl hydroxylations of HIF-1α enable it to be ubiquitinylated by the von Hippel Lindau factor (VHL) and quickly degraded in proteasomes. 142 Hypoxia slows these prolyl hydroxylations, thereby prolonging the survival of HIF-1α. Acting in concert with its constitutively expressed heterodimer partner HIF-1β, HIF-1α stimulates transcription of VEGF, matrix proteases, the glucose transporters GLUT1 and GLUT3, as well as a number of glycolytic enzymes; these adaptations aid survival of hypoxic cancer cells by promoting angiogenesis while boosting glycolytic ATP generation. [143] [144] [145] Overexpression of HIF-1α is common in cancers and may be largely responsible for the phenomenon of "aerobic glycolysis" described long ago by Warburg. 146 Not surprisingly, overexpression of HIF-1α has been linked to poor prognosis in many types of cancer, [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] albeit prostate cancer has not yet been investigated in this regard.
Expression of HIF-1α protein has been found to be increased in prostate intraepithelial neoplasia and in prostate cancers, relative to the levels seen in healthy prostate epithelium and benign prostatic hyperplasia. [158] [159] [160] [161] This is readily predictable, owing to the fact that both the PI3K-Akt-mTOR-p70S6 kinase pathway and Erk1/2 enhance the synthesis/activity of HIF-1α. The former pathway accelerates the translation of HIF-1α mRNA, 162, 163 whereas MAP kinases increase the intranuclear transport and transactivating activity of HIF-1α. [164] [165] [166] [167] Transcription of the HIF-1α gene can be stimulated by diacylglycerol-dependent isoforms of protein kinase C. 168 Modulation of these pathways has the expected impact on HIF-1α in human prostate cancer cells. [169] [170] [171] [172] [173] Gene amplification may contribute to high HIF-1α expression in some prostate cancers. 159 In addition, mutations leading to altered structure of the HIF-1α protein domain required for ubiquitinylation have been observed in 2 prostate cancers; the functional significance of these mutations awaits clarification. 174 The ubiquitous heat shock protein Hsp90 binds to HIF-1α, and there is recent evidence that this interaction stabilizes the latter, preventing its ubiquitinylation and proteasomal degradation by VHLindependent mechanisms. 175 The Hsp90 antagonist geldanamycin, an antibiotic that inhibits Hsp90 function by suppressing its ATPase activity, disrupts the interaction between Hsp90 and HIF-1α and presumably as a consequence accelerates proteasomal degradation of HIF-1α under both hypoxic and normoxic circumstances in PC-3 and LNCaP cells in vitro. 176 The geldanamycin derivative 17-N-allylamino-17demethoxygeldanamycin (17-AAG) has been shown to inhibit growth of prostate cancer xenografts in nude mice, in doses that appeared to be well tolerated. 177 This effect may not solely reflect downregulation of HIF-1α, as 17-AAG was shown to decrease tumor expression of other oncogenic proteins that are stabilized by Hsp90, including HER-2, Akt, and the androgen receptor. (Indeed, Workman notes that Hsp90 inhibitors can "block multiple mission critical oncogenic pathways in the cancer cell" 178 ; these considerations suggest that 17-AAG or other Hsp90 inhibitors may demonstrate versatile utility in MSMTs.) Accelerated degradation of the androgen receptoran effect that potentially could aid control of both androgen-dependent and -independent tumors-has also been demonstrated in geldanamycin-treated LNCaP cells. 179 Another recent study reports an additive or synergistic interaction of 17-AAG and xirradiation with respect to induction of growth delays in human prostate cancer spheroids in vitro. 180 17-AAG is currently in clinical evaluation and is said to have shown an acceptable toxicity profile in phase I studies. 181 Hepatotoxicity is dose limiting; this complication does not appear to be intrinsic to Hsp90 inhibition, as other inhibitors of this factor have not been hepatotoxic in rodents.
HIF-1α can also be downregulated by measures that decrease the activity of either p70S6 kinase or Erk1/2. mTOR inhibitors and strategies that suppress the activity of tyrosine kinase hormone receptors can suppress p70S6 kinase activation. Erk1/2 activity can be downregulated by decreasing the activity of tyrosine kinase receptors and/or protein kinase A. Cox-2 inhibition should be helpful with regard to the latter strategy (see below), and indeed, nonsteroidal antiinflammatory drugs are reported to decrease HIF-1α level and activity in PC-3 and DU145 cells. 182 Physiological levels of ascorbate and of iron are required for catalysis of the ubiquitinylation reactions that decrease HIF-1α half-life. 183 However, there currently is no evidence that supplemental intakes of either of these nutrients can influence HIF-1α activity in subjects not markedly deficient in them.
Suppression of HIF-1α activity would appear to be a critical component of successful angiostatic regimens. Whether levels of HIF-1α are elevated in a relatively normoxic tumor, the tumor hypoxia that will be the inevitable result of inhibiting the angiogenic response to that tumor will upregulate HIF-1α activity, evoking a compensatory production of angiogenic factors while improving the ability of hypoxic cancer cells to maintain energy homeostasis. Once Hsp90 inhibitors are indeed approved for clinical use (as appears likely based on initial clinical assessments), they may become important adjuvants for angiostatic strategies such as copper depletion. A portion of the angiostatic activity of geldanamycin analogs may be attributable to a direct impact on endothelial cells. 184 
Hsp90
Hsp90 merits further consideration here, in light of its versatile impact on oncogenic signaling pathways. In conjunction with other chaperone molecules, Hsp90 forms so-called "closed conformation" complexes with a number of client proteins; these complexes protect the client proteins from proteasomal degradation and in some instances enhance their metabolic activities. Hsp90 inhibitors such as geldanamycin analogs bind to Hsp90 in such a way as to prevent the formation of these closed conformation complexes, thereby destabilizing Hsp90 client proteins. A large number of enzymes are stabilized by Hsp90 complexes, including many that participate in oncogenic signaling. 178, 185 These include enzymes involved in tyrosine kinase signaling (IGFR1, ErbB2, VEGFR2, c-src), the mitogenactivated protein (MAP) kinase pathway (raf-1, B-raf, MEK), the PI3K pathway (PDK1, Akt), and NF-κB signaling (the IκB kinases). Other proteins stabilized by Hsp90 complexes include steroid receptors (including androgen and estrogen receptors), Stat3, p53, Apaf-1 (a mediator of mitochondrially triggered apoptosis), MDM2, and of course HIF-1α. These proteins vary in the degree to which Hsp90 inhibition reduces their half-lives and activities; it should not be assumed that clinically tolerable concentrations of Hsp90 inhibitors will have a functionally important impact on each of these proteins.
Remarkably, the affinity of Hsp90 for 17-AAG is far higher in cancer cells than in normal cells, apparently because, for reasons that remain obscure, most Hsp90 in transformed cells is associated with various cochaperones that alter its configuration. 185, 186 (This phenomenon has been demonstrated with a number of rodent and human cancer cell lines, as well as clinical samples from breast and colon carcinomas, albeit prostate cancers were not examined in these studies.) Thus, the impact of geldanamycin analogs may be somewhat tumor selective. Other small-molecule inhibitors of Hsp90 are being developed; it is not yet known whether they will share this property of geldanamycin analogs. 185 The potential of Hsp90 inhibitors to address a range of oncogenic signaling pathways is so striking as to suggest that these agents might be viewed as MSMTs in and of themselves! In the words of Zhang and Burrows, "Targeting Hsp90, a central regulatory node in oncogenic signal transduction, is an exciting and novel approach to pleiotropic intervention in cancer." 185(p496) 
Cyclooxygenase-2 (Cox-2)
Many, though not all, 187, 188 researchers have concluded that cox-2 is overexpressed in prostate cancers relative to normal prostate epithelium or benign prostatic hyperplasia. [189] [190] [191] [192] This is likely a logical consequence of the fact that both NF-κB and AP-1 (activated by Erk1/ 2) can bind the cox-2 promoter and boost transcription of the cox-2 gene. [193] [194] [195] Numerous studies conclude that inhibition of cox-2 slows proliferation and/or upregulates apoptosis in both androgendependent and -independent human prostate cancer cell cultures [196] [197] [198] [199] [200] ; inhibition of prostate cancer xenografts in nude mice with cox-2 inhibitors has also been reported. 198, 201 A portion of the efficacy demonstrated in these studies, however, reflects extraneous effects of specific cox-2 inhibitors, independent of cox-2 inhibition, seen at high dose levels. [202] [203] [204] [205] Thus, celecoxib has often shown greater tumor-retardant activity than other cox-2 inhibitors that are comparably effective for cox-2 inhibition.
Relatively few studies have addressed the molecular mechanisms responsible for the growth-inhibitory effects of cox-2 inhibition on prostate cancer. Prostaglandin E2 (PGE2) is the predominant cyclooxygenase product of both healthy and malignant prostate tissue. 206 The receptors for PGE2 expressed by human prostate cancer cell lines appear to be of the EP2 and EP4 subtypes, 207 both of which are linked to stimulation of adenylate cyclase via Gα s . 208 Thus, it is reasonable to presume that downregulation of cAMP mediates the impact of cyclooxygenase inhibition on prostate cancer. Although cAMP inhibits MAP kinase activation in some cell types, it can potentiate growth factor-mediated activation of MAP kinase in malignant or rapidly proliferating cells that typically express the type I isoform of PKA (as discussed below) 76 ; thus, upregulation of MAP kinase activity may mediate at least some of the impact of cyclooxygenase activity on prostate cancer cells. PGE2 enhances the nuclear translocation and transcriptional activity of HIF-1α in PC-3 cells, an effect mediated by activation of the MAP kinase pathway. 165 PGE2 and cAMP promote the transcription of VEGF and other angiogenic factors, likely reflecting the presence of HIF-1 and AP-1 response elements in the VEGF promoter 144, [209] [210] [211] ; they also boost expression of the key survival factor Bcl-2. 212 The cox-2 inhibitor NS398 decreases expression of bcl-2 protein in LNCaP cells 196 and suppresses the hypoxia-induced upregulation of VEGF in a highly metastatic subline of PC-3 cells; this latter effect was abrogated by concurrent treatment with PGE2. 213 Downregulation of VEGF expression in PC-3 xenografts with this drug has also been reported. 201 Cox inhibitors have also been shown to suppress the invasiveness of DU145 and PC-3 cells in vitro by downregulating metalloproteinase expression; once again, concurrent PGE2 reversed this effect. 214, 215 The first published pilot clinical trial of cox-2 inhibition in prostate cancer has yielded encouraging results. 216 Twelve patients who had chemical relapse after radiation therapy or radical prostatectomy were treated with celecoxib 200 mg twice daily. After 3 months of treatment, PSA levels had fallen or stabilized in 8 of the patients; 3 of the remaining 4 patients experienced a marked decrease in PSA doubling time. The authors concluded that "cox-2 inhibitors may help to delay or prevent disease progression in these patients, and thereby help extend the time until androgen deprivation therapy." 216(p275) Also worthy of mention is an in vitro study demonstrating that saw palmetto berry extract inhibits the growth of several human prostate cancer cell lines, an effect associated with decreased expression of both cox-2 and bcl-2. 217
PKA Type I
PGE2 is not the only autocrine/paracrine factor that can activate adenylate cyclase in prostate cancer; vasoactive intestinal peptide, pituitary adenylate cyclaseactivating polypeptide, parathyroid hormone-related peptide, calcitonin, and calcitonin gene-related peptide have this potential as well. [218] [219] [220] [221] [222] [223] [224] Moreover, since most prostate cancers express at least modest amounts of cox-1, 190, 191 complete suppression of cox-2 activity would not wholly suppress autocrine PGE2 production. Thus, cox-2 inhibition could not be expected to eliminate adenylate cyclase/protein kinase A activity in prostate cancer.
Most cancers and other proliferating cells express the type I PKA (PKA-I), whereas type II PKA predominates in quiescent cells. 225 These 2 forms of PKA share a common catalytic subunit but are distinguished by their regulatory subunits: RI and RII, respectively. When cells are in a proliferative mode, growth factor activity somehow selectively boosts expression of RI, such that it outcompetes RII for binding to the catalytic subunit of PKA. Possibly owing to differences in subcellular location-PKA-I is linked to EGFR via its RI subunit 226 -PKA-I and PKA-II have distinctive activities. In particular, PKA-I acts as a cogrowth factor, aiding activation of MAP kinase, boosting proliferation, suppressing apoptosis, and promoting production of angiogenic factors as well as the multidrug-resistant protein mdr-1. 76, [225] [226] [227] [228] When expression of RI is downregulated (as with antisense agents or 8-Cl-cAMP), there is a compensatory upregulation of the RII subunit, such that PKA-II replaces PKA-I, leading to a more quiescent phenotype. Antisense agents targeting the RIα subunit of PKA-I, configured in ways that render them more stable, better tolerated, and susceptible to oral administration-so-called secondgeneration mixed backbone oligonucleotides-are now being developed as clinical anticancer agents. 229 The results of phase I studies with one of these, GEM 231, have been described. 230, 231 (This agent was 1 of the 3 employed in the Tortora study cited above.)
As noted previously, Mimeault et al have reported that concurrent inhibition of PKA and EGFR synergistically suppresses proliferation and boosts apoptosis in EGF-and serum-stimulated human prostate cancer cell lines (LNCaP, DU145, and PC-3). 81 A similar phenomenon has been demonstrated by Tortora's group in other human cancer cell lines and xenografts, using antisense agents or 8-Cl-cAMP to antagonize PKA-I activity. [232] [233] [234] Although GEM 231 is partially absorbable after oral administration, initial clinical trials have evaluated intermittent slow continuous infusions of this agent. 231 Elevations of transaminases and alterations in coagulation parameters are dose limiting, and a low-grade, reversible fatigue is a common side effect. While the plasma half-life of GEM 231 is about 1 hour, tissue halflife is thought to be far longer. Theoretically, orally absorbable agents that are well tolerated during chronic administration should yield the best results in signal modulation therapy. Nonetheless, it may prove feasible and worthwhile to incorporate intermittent courses of parenterally administered antisense agents into such regimens, if such courses can trigger a substantial temporary increase in tumor apoptosis that promotes tumor regression or synergize with concurrently administered cytotoxic agents.
Vascular Endothelial Growth Factor (VEGF)
VEGF is widely viewed as the most functionally significant angiogenic factor. Histological studies of human prostate cancers conclude that VEGF expression correlates with microvessel density in these tumors, [235] [236] [237] [238] and specific VEGF antagonists slow the growth of human prostate cancer xenografts in nude mice [239] [240] [241] findings consistent with an important role for VEGF in the angiogenic response to prostate cancer. VEGF may also have autocrine growth factor activity for some prostate cancers.
The human VEGF promoter has received considerable study. 211 As noted above, the transcription factors NF-κB and HIF-1 bind to this promoter and boost VEGF transcription. Response elements for AP-1, Sp1, and STAT3 are also found in this promoter, and these transcription factors likewise promote VEGF transcription. 209, 210, [242] [243] [244] [245] [246] [247] Although AP-2 can also bind to the VEGF promoter, it appears to have an inhibitory impact on VEGF transcription in prostate cancers, consistent with the observation that expression of AP-2 is typically diminished in advanced prostate cancers. 248 These findings imply that an optimally comprehensive strategy for downregulating VEGF production by prostate cancers will entail suppression of the transactivational activities of NF-κB, HIF-1, AP-1, Sp1, and STAT3. Agents that downregulate the former 2 transcription factors have been discussed above. As is well known, Erk1/2 and c-Jun-N-terminal kinase contribute importantly to AP-1 activity. Thus, measures for downregulating the MAP kinase signaling pathway should be helpful in this regard. These include measures that suppress the activities of tyrosine kinase growth factor receptors (such as IGFR-1 and EGFR), farnesyl:protein transferase (required for ras activity, see below), cox-2, and PKA type 1. Hsp90 inhibitors may also aid control of Erk1/2 activity, as they have the potential to decrease the stabilities of IGFR1, ErbB2, raf-1, B-raf, and MEK. 185 With respect to Sp1, Erk1/2 boosts its transactivational activity via threonine phosphorylations. 249, 250 The PI3K pathway may also contribute in this regard, as PKCζ, downstream from PI3K/PDK-1, can also induce an activating phosphorylation of Sp1. 251 Inhibition of c-Src kinase may decrease STAT3 activation, as discussed below.
In brief, therapies that simultaneously downregulate NF-κB, HIF-1α, Erk1/2, and STAT3 activities can be expected to have a substantial impact on VEGF expression. Such measures should also suppress the activities of a number of other transcription factors implicated in prostate cancer angiogenesis, including basic fibroblast growth factor, 235 responsive to the transcription factor early growth response-1 (Egr-1). 252, 253 Like c-fos, Egr-1 is rapidly induced by Erk1/2 activity.
5-Lipoxygenase (5LPO)
There are 2 reports that, as contrasted to benign prostate tissue, 5LPO is markedly upregulated in prostate cancers and prostatic intraepithelial neoplasia. 254, 255 Ghosh and colleagues have demonstrated that 5(S)-HETE, a major product of 5LPO, has growth factor activity for both androgen-dependent and -independent prostate cancer cell lines and that, conversely, selective inhibitors of 5LPO promote apoptosis in these cells, an effect reversed by administration of 5(S)-HETE. [256] [257] [258] Other groups have confirmed that 5LPO inhibition suppresses proliferation and promotes apoptosis in prostate cancer cells in vitro 259, 260 ; however, one group found no effect of such inhibition on survival of PC-3 cells. 261 So far, there do not appear to be any published studies examining the impact of 5LPO inhibition on prostate cancer xenografts. Clinical tools for suppressing 5LPO activity are available: boswellic acids, the key ingredients of salai guggal, an ancient Ayurvedic remedy used in inflammatory disorders, have been shown to be potent inhibitors of this enzyme, 262 and commercially available extracts rich in boswellic acids have shown clinical efficacy in asthma, presumably reflecting inhibition of 5LPO-dependent leukotriene production. 263 The drug zileuton likewise inhibits 5LPO and is useful in asthma management. 264 Studies evaluating the impact of these agents on prostate cancer xenografts are evidently needed.
How does 5(S)-HETE act as a growth and survival factor? The membrane receptor for this compound in prostate cancer (PC-3) appears to be a 7-pass receptor that activates pertussis toxin-sensitive G proteins yet is distinct from that expressed by leukocytes. 265 This receptor somehow activates both the PI3K-Akt and MEK-Erk1/2 pathways. In a pancreatic cancer cell line responsive to 5(S)-HETE, pertussis toxin, tyrosine kinase inhibition, and inhibitors of PI3K and of MEK block the growth response to 5(S)-HETE. 266 Thus, 5(S)-HETE appears to function like a tyrosine kinaseactivating growth factor, even though its receptor is not a tyrosine kinase; presumably, a tyrosine kinase is activated downstream of a G protein.
Ghosh has observed that the ability of selenium to promote apoptosis in human prostate cancer cell lines is abrogated by treatment with 5-(S)-HETE. 267 Thus, he suggests that the efficacy of selenium for prevention or treatment of prostate cancer may be amplified by concurrent administration of 5LPO inhibitors.
12-Lipoxygenase (12LPO)
Overexpression of the so-called platelet isoform of 12LPO has been observed in about half of prostate cancers and tends to correlate with aggressive tumor behavior. 268, 269 The chief product of this enzyme, 12(S)-HETE, exerts both autocrine and paracrine effects, presumably mediated by an as-yet uncharacterized receptor. In both PC-3 and DU145 cells, prolonged inhibition of 12LPO-with 25 µM of either the natural flavone baicalein or the drug BHPP-is associated with a marked reduction of proliferation characterized by accumulation of cells in G1 phase, as well as upregulation of apoptosis; decreased expression of D cyclins as well as of the antiapoptotic proteins Bcl-2 and survivin is observed, and presumably contributes to these effects. 270 Co-incubation with 12(S)-HETE prevents these effects of 12LPO inhibition. Overexpression of 12LPO in prostate cancer cell lines leads to constitutional activation of NF-κB, as well as increased membrane expression of the vitronectin-binding integrins α v β 3 and α v β 5 . 261, 271 The latter effect enables 12LPO-transfected PC-3 cells to avoid apoptosis when cultured in serum-free medium; the ligand-bound integrins transmit a survival signal. Increased expression of these integrins also boosts the ability of prostate cancer cells to adhere to substratum, migrate, and invade Matrigel, 272 consistent with the more aggressive behavior seen with 12LPO-overexpressing prostate cancers. 268, 273 In vivo, 12LPO-transfected PC-3 cells are more invasive and metastatic and evoke a stronger angiogenic response 272 ; conversely, preincubation of prostate cancer cells with 12LPO inhibitors blunts their metastatic potential when they subsequently are injected into mice. 273 Perhaps of more general interest is the fact that 12LPO is expressed in human endothelial cells and appears to play a key role in angiogenesis. [274] [275] [276] Exposure of endothelial cells to angiogenic factors induces release of arachidonic acid from membrane phospholipids, which in turn promotes synthesis of 12(S)-HETE. The latter induces membrane expression of vitronectin-binding integrins, as it does in prostate cancer cells 274 ; these integrins are crucial to the angiogenic process. 277 In vitro, 12LPO inhibitors suppress the mitogenic, migratory, and tube-forming response of endothelial cells to VEGF and bFGF. 276, 278 Conversely, 12LPO-transfected endothelial cells are more responsive to angiogenic signals. 276 This suggests that the 12(S)-HETE elaborated by cancer cells could promote the angiogenic response, consistent with the greater microvessel density noted in tumors derived from 12LPO-transfected PC-3 cells. 272 In the chorioallantoic membrane assay, pretreatment with baicalein dose dependently inhibited the angiogenic response to bFGF. 278 These considerations suggest that effective 12LPO inhibition, if clinically achievable, would have general therapeutic utility as an angiostatic measure and would be of particular value in prostate cancers that overexpress 12LPO. Unfortunately, no studies of 12LPO inhibition in prostate cancer xenografts have been reported, but the growth of a 12LPO-expressing human pancreatic cancer xenograft was inhibited by about 50% when mice were repeatedly gavaged with baicalein (250 mg/kg/d). 279 Whether a sufficiently high (but tolerable) oral intake of baicalein could maintain adequate inhibition of 12LPO in humans remains to be seen; like other flavonoids, baicalein may be rapidly conjugated with glucuronic acid or sulphate in vivo. Intriguingly, baicalein is one of the chief flavonoids in Scutellaria baicalensis, an herb featured prominently in certain herbal mixtures used traditionally for cancer therapy in East Asia. 278 In any case, development of a clinical regimen for effective 12LPO inhibition should be a high research priority.
Angiotensin II Receptor Type 1
Angiotensin II (Ang II), acting via type 1 receptors (AT-1), has been shown to have an upregulatory impact on tumor-evoked angiogenesis; this reflects direct effects of Ang II on both endothelial cells as well as the cancer. [280] [281] [282] [283] [284] The role of Ang II in support of prostate cancer induction and progression has so far received little study. However, Uemura and colleagues have recently reported that AT-1 expression is upregulated in most human prostate cancers in comparison to healthy prostate tissue. 285 They further showed that Ang II promoted proliferation of human prostate cancer cell cultures, an effect associated with increased phosphorylation of MAP kinase and of STAT3. This effect was inhibited by concurrent administration of AT-1 blocker drugs, which remarkably also diminished the proliferative response to EGF. Finally, they showed that AT-1 blockers dose dependently inhibited the growth of prostate cancer xenografts in nude mice, an effect associated with decreased microvessel density in the tumors.
Although few studies have examined the signaling mechanisms evoked by the AT-1 receptor in benign or malignant prostate epithelium, this receptor activates both the PI3K-Akt and MAP kinase pathways in smooth muscle cells, even though AT-1 is a 7-pass Gprotein-linked receptor (like that for 5-(S)-HETE). 286 Activation of the soluble tyrosine kinase c-Src may mediate the growth factor activity of AT-1 in smooth muscle. 287, 288 In human prostate stromal cells, which express AT-1, this receptor induces proteolytic cleavage and release of the membrane-bound precursor form of heparin-binding EGF; this in turn activates the EGF receptors ErbB1 and ErbB2. 289 EGFR also acts as a mediator of the mitogenic activity of Ang II in human breast cancer cells. 77 The possibility that expression of angiotensin I converting-enzyme (ACE) influences human prostate cancer risk has been suggested by a recent epidemiological study examining the influence of an insertion/deletion polymorphism of the ACE gene. 290 The DD genotype, associated with increased expression of ACE, was found to be associated with a significant increase in risk for advanced prostate cancer (odds ratio = 2.18). A previous study had found a trend toward reduced prostate cancer risk in longterm users of the ACE-inhibitory drug captopril; albeit other types of ACE inhibitors did not appear to influence risk in this study. 291
Bradykinin Receptor Type 1
The somewhat equivocal impact of ACE inhibition on prostate cancer risk in epidemiological studies to date may reflect the fact that bradykinin, whose catabolism is mediated by ACE, has growth factor activity for some prostate cancers. The type 1 bradykinin receptor, not found in benign prostate tissues, is expressed by prostatic intraepithelial neoplasia as well as more advanced prostate cancers 292 ; prostate cancers also express tissue kallikrein, enabling local generation of bradykinin. 293 In PC-3 cells, bradykinin promotes proliferation, migration, and invasion via the type 1 receptor. 292, 294 This effect is mediated by activation of Erk1/2, which in turn requires upstream activation of PKC and EGFR. 294 An antagonist to the type 1 bradykinin receptor slows the growth of PC-3 xenografts in nude mice. 295, 296 These considerations suggest that downregulation of angiotensin II's impact on prostate cancer proliferation and angiogenesis may be best achieved with drugs that selectively block the AT-1 receptor, rather than with ACE inhibitors that would be expected to increase bradykinin levels. This conclusion draws further support from evidence that the endothelial AT-2 receptor acts to suppress angiogenesis 297 ; thus, when AT-1 receptors are effectively blocked, Ang II may have net angiostatic activity.
c-Src
The receptors for PGE2, 5-LPO, and Ang II are members of the large class of G protein-coupled receptors (GPCRs), a number of which are expressed by prostate cancer cells. 298, 299 These include receptors for bombesin, a prominent autocrine growth factor in the many prostate cancers containing neuroendocrinedifferentiated cells. [300] [301] [302] [303] Intriguingly, the increase in the proliferation of PC-3 cells evoked by exposure to 10% fetal bovine serum is almost completely eliminated by pretreatment with pertussis toxin, implying that Gi-coupled receptors are responsible for the bulk of the mitogenic impact of serum exposure. 304 The mechanisms by which GPCRs transmit mitogenic signals are still somewhat obscure, but transactivation of the EGFR, mediated at least in part by the nonreceptor tyrosine kinase c-Src, often appears to play a key role in this regard. Indeed, serum-stimulated activation of Erk1/2 in PC-3 cells was decreased by 30% to 40% when the cells were treated with PP2, a relatively specific inhibitor of Src family kinases, and inhibition of EGFR almost completely abrogated this activation. 304 Joint overexpression of c-Src and EGFR in cancers is associated with highly aggressive behavior, and this likely reflects a key role for c-Src in full activation of EGFR. [305] [306] [307] Activated c-Src can phosphorylate 2 tyrosine residues in EGFR-Tyr-845 and -1101-not susceptible to autophosphorylation. The functional impact of Tyr-1101 phosphorylation remains unclear. c-Src-mediated phosphorylation of Tyr-845 may be more consequential; although it does not influence EGF-mediated activation of MAP kinases, it greatly potentiates the mitogenic response to EGFR agonists. 306 In cells transfected with a Y845F mutant EGFR (ie, in which Tyr-845 is replaced by phenylalanine) or a kinase-inactive c-Src, the proliferative response to both EGF and serum is greatly reduced. 306, 308 There is some evidence that Tyr-845 phosphorylation may be crucial for EGFR-mediated activation of STAT3 309 ; indeed, there are many reports that c-Src inhibition compromises the ability of EGF agonists to activate this transcription factor. [309] [310] [311] [312] [313] STAT3 has the potential to contribute to malignant behavior, as it boosts transcription of cyclin D1, c-myc, VEGF, and the antiapoptotic proteins Bcl-xL and mcl-1 [245] [246] [247] 314, 315 ; it also amplifies androgen receptor-mediated transcription. [316] [317] [318] [319] STAT3 tends to be constitutively activated in androgen-independent prostate cancers, [320] [321] [322] and antisense suppression of STAT3 expression, or transfection with dominant negative STAT3, markedly decreases the proliferation of prostate cancer cells while promoting apoptosis. 320, 321, 323, 324 The activated EGFR can itself activate c-Src, through binding of the latter to receptor phosphotyrosines via its SH2 domain; thus, EGFR and c-Src are mutually stimulatory. How activated c-Src transactivates EGFR in the absence of EGFR agonists-to enable MAP kinase activation 304, [325] [326] [327] [328] remains unclear; presumably, it produces a phosphotyrosine docking site for Grb2/Sos/Ras, on EGFR or some associated protein such as Shc. (Activated c-Src can produce analogous docking sites in other signaling proteins, including Shc and the focal adhesion kinase Pyk2.) 329, 330 GPCRs also can activate c-Src; Gαs and Gαi are reported to achieve this by direct association, 331 Gβγ may also be active in this regard, 304, 332, 333 and PKAstimulated by Gαs-activates c-Src via phosphorylation of Ser-17. 334, 335 (Recall that type I PKA associates with the EGFR; this would enable PKA to activate c-Src in the immediate vicinity of this receptor.) In cells that express B-raf (the status of prostate cancer in this regard appears to be unknown), activated c-Src can stimulate the MAP kinase pathway by activating Rap1, which in turn activates B-raf. 335 c-Src also promotes cell migration through its interactions with integrins and focal adhesion kinase [336] [337] [338] ; thus, inhibition of c-Src may have potential for combating the metastatic spread of cancer as well as tumor-evoked angiogenesis. 339 Remarkably, c-Src knockout mice are fairly healthy; their chief problem is that their osteoclast function is impaired, leading to osteopetrosis. 340 Two conclusions have been drawn from this: first, that a sufficiently potent and specific inhibitor of c-Src might be reasonably well tolerated as a therapeutic agent; second, that such inhibitors might have utility for treatment of osteoporosis. The most selective inhibitors of c-Src yet developed are the pyrollopyrimidines CGP77675 and CGP76030 341, 342 ; these are now being employed in rodent studies 343 but have not yet been studied clinically. PP2, an inhibitor of the family of Src kinases, has been administered to nude mice bearing human colon cancer xenografts; this treatment inhibited growth of the primary tumors by about 50%, while almost totally preventing hepatic metastases, and was not associated with any evident toxicity. 344 Two published studies have examined the impact of c-Src inhibitors on human prostate cancer cell lines; the influence of c-Src inhibition on prostate cancer xenografts has not yet been assessed. CGP77675 and CGP76030 both dose dependently decrease the proliferation rate of PC-3 cells; they also decrease the ability of these cells to adhere and spread on Matrigel and to invade this substrate. 342 A previous study had likewise shown that PP2 slows the migration of both PC-3 and DU145 cells. 337 With respect to the contemplated clinical use of c-Src inhibitors in prostate cancer, it has been suggested that the antiosteoclastic impact of such a therapy might lessen the tendency of prostate cancer to metastasize to bone. 342 Owing to its role in transmitting mitogenic signals from GPCRs, its ability to amplify the oncogenic activity of EGFR, and its key role in cellular migration, c-SRC may be an attractive target for signal modu-lation therapy of cancer. 340, 345 However, realization of this prospect must await the clinical development of highly specific c-Src inhibitors.
Interleukin-6 (IL-6)
Overactivation of c-Src is not the sole reason for upregulated activation of STAT3 in prostate cancer; autocrine or paracrine IL-6 can also promote STAT3 activation. Autocrine production of IL-6 has been noted in androgen-independent human prostate cancer cell lines 346, 347 -though not androgen-dependent LNCaP cells 346, 348 -as well as in human prostate cancer biopsies. 348, 349 IL-6 protein was reported to average 18fold higher in clinically localized prostate cancers as compared to healthy prostate tissue. 348 Moreover, human prostate cancers and cancer cell lines almost uniformly express the IL-6 receptor, 347, 349, 350 giving rise to an IL-6 autocrine loop. Although the impact of IL-6 on LNCaP cells has been inconsistent, 346, 351, 352 IL-6 has been found to promote proliferation and suppress apoptosis in androgen-independent prostate cancer cell lines, 346, 347 reflecting IL-6-mediated activation of STAT3 and MAP kinase signaling pathways. 353 Upregulation of Bcl-xL is primarily responsible for the antiapoptotic effect, and this upregulation in turn is primarily attributable to increased STAT3 activity. 354, 355 IL-6's ability to boost the transcriptional activity of androgen receptors, even when androgen levels are very low or absent, 352, [356] [357] [358] is also largely mediated by STAT3. 357 Thus, androgen deprivation may select for prostate cancer cells that overexpress IL-6. When nude mice bearing PC-3 xenografts were treated with monoclonal antibody targeting IL-6, growth of the tumor was inhibited by approximately 60% 359 ; such antibodies also slow proliferation of prostate cancer cell lines in vitro and sensitize them to chemotherapeutic agents. 346, 360 Serum levels of IL-6 and of IL-6 receptors are typically elevated in patients with advanced prostate cancer, particularly bone metastases, and correlate with poor prognosis. 347, 361, 362 In the PC-3 and DU145 cell lines, increased activity of the IL-6 promoter has been traced to constitutive upregulation of NF-κB and AP-1 transcription factors. 363 Thus, the constitutive activation of NF-κB typical of androgen-independent prostate cancers may promote androgen independence via upregulated IL-6 and STAT3. Conversely, therapeutic measures that suppress NF-κB activation in prostate cancer could be expected to decrease tumor production of IL-6 and thus suppress the IL-6 autocrine loop. In this regard, copper deprivation with TM (reported to decrease NF-κB activity in cancer) decreased IL-6 production by a human breast cancer xenograft in nude mice. 136 Thus, TM therapy, as well as other measures that downregulate NF-κB, may help to control IL-6/STAT3 overactivity in prostate cancer.
There is suggestive evidence that an autocrine loop involving IL-11, likewise an NF-κB-inducible cytokine, 364 may also contribute to STAT3 overactivation in prostate cancer. 365, 366 
Ras
Although oncogenic constitutively active mutants of Ras are commonly encountered in some types of cancer, they appear to be relatively rare in human prostate cancers, with the possible exception of Japanese patients. [367] [368] [369] Statin therapy, which can downregulate the activity of Ras by opposing its isoprenylation, has not been associated with decreased risk for prostate cancer. 370, 371 Nonetheless, a drug that inhibits farnesyl:protein transferase, causing the cytoplasmic accumulation of Ha-Ras, has been shown to have growthinhibitory effects on a range of human prostate cancer cell lines. 372 This effect was seen in lines that lacked a mutant Ras, but the drug literally reversed the neoplastic phenotype in TSU-Pr1 cells, which express an oncogenic Ha-Ras mutant. Thus, it may be worthwhile to devote further study to farnesyl:protein transferase inhibitors (or other agents that interfere with isoprenylation) as potential components of multifocal signal modulation therapies for prostate cancer; several of these inhibitors have already been evaluated in phase I and phase II clinical studies. 373, 374 
Apoptosis Suppressors: MDM2 and Bcl-2/Bcl-xL
The excessive growth and resistance to cytotoxic chemotherapy that characterize many cancers often reflect increased expression or activation of proteins that downregulate apoptosis. These proteins can be targeted with antisense agents.
p53 is activated by signals that detect unrepaired DNA damage or excessive growth factor stimulation; depending on the circumstances, p53 either slows the cell cycle to prevent entry into S phase (via p21) or triggers apoptosis. The activity of p53 is opposed by MDM2, which binds to p53 and ubiquinylates it, routing it to proteasomal destruction. MDM2 suppresses apoptosis in other ways, independent of p53, that are still poorly understood; there is recent evidence that MDM2 promotes proteasomal degradation of p21. 375 In a series of 118 localized prostate cancers obtained by prostatectomy, 40% were found to overexpress MDM2, and these tumors tended to be larger than the others. 376 A mixed-backbone oligonucleotide antisense agent targeting MDM2 has been studied in human prostate cancer cells and xenografts. [377] [378] [379] [380] [381] [382] This agent was found to decrease proliferation and increase apoptosis in LNCaP (expressing wild-type p53), DU145 (expressing mutant p53), and PC-3 (not expressing p53); thus, the efficacy of MDM2 suppression appears to be independent of p53 status. 378 This agent also sensitized these cells to the cytotoxicity of a taxane and a topoisomerase inhibitor and slowed the growth of LNCaP and PC-3 xenografts in nude mice. Other studies have established that MDM2 antisense can boost the apoptotic response of prostate cancer cells to androgen deprivation and sensitize these cells to radiotherapy. [379] [380] [381] Finally, Tortora and colleagues have shown that MDM2 antisense potentiates response to the EGFR inhibitor Iressa in human prostate cancer cell lines and xenografts. 382 Bcl-2 and its close relative Bcl-xL, which oppose mitochondrially triggered apoptosis, have also been targeted with a mixed backbone oligonucleotide antisense agent that can suppress synthesis of both of these proteins. 383, 384 This agent complements the tumor-retardant activity of PKA-RI antisense in nude mice implanted with human colon cancer xenografts. 383 Histological studies have found overexpression of bcl-2 in about 30% of prostate cancers, and, not surprisingly, this overexpression tends to correlate with malignant behavior and poorer prognosis. [385] [386] [387] [388] Thus, there may be a role for bcl-2/bcl-xL antisense in the management of selected prostate cancers.
A review of antisense strategies potentially of use in prostate cancer treatment has appeared recently. 389 
Vitamin D Receptor
Normal prostate epithelium expresses vitamin D receptors, and calcitriol, the natural agonist for these receptors, exerts a growth-inhibitory effect. [390] [391] [392] These cells also express 1-α-hydroxylase activity and thus can generate their own calcitriol from circulating 25hydroxycholecalciferol. 391, 393, 394 Since the serum level of 25-hydroxycholecalciferol is determined largely by exposure of skin to ultraviolet light, these findings have encouraged the speculation that good vitamin D status might reduce prostate cancer risk. Although epidemiological studies correlating assessed sunlight exposure with subsequent prostate cancer risk are reasonably supportive of this thesis, [395] [396] [397] [398] [399] [400] [401] prospective studies examining serum levels of calcitriol or 25hydroxyvitamin D have been much less so. [402] [403] [404] [405] [406] [407] Thus, the role of vitamin D status in prostate cancer induction remains unclear. Since supraphysiological concentrations of calcitriol have been employed in most in vitro studies, it is conceivable that the growthinhibitory impact of this hormone on prostate epithelium is pharmacological rather than physiological.
Calcitriol, and less calcemic synthetic agonists for the vitamin D receptor, likewise have a growth-inhibitory effect on most human prostate cancer cell lines and on prostate cancer xenografts in nude mice. [408] [409] [410] [411] [412] [413] [414] [415] [416] Calcitriol's efficacy in this regard varies considerably depending on the cell line studied; variations in vitamin D receptor expression often do not account for differences in response. Androgen-dependent cell lines tend to be more responsive than those that are androgen independent, for reasons that remain obscure. 408, 417 Owing to the fact that 1-α-hydroxylase is nearly inactive in prostate cancer, 25-hydroxycholecalciferol does not influence proliferation in these cells. 418 The growth-retardant impact of calcitriol on prostate cancers and normal epithelium appears to be mediated primarily by an increase in IGFBP-3 synthesis, 412, [419] [420] [421] reflecting the presence of a functional vitamin D response element in the IGFBP-3 promoter. 422 While IGFBP-3 can influence prostate function by limiting the availability of IGFs, it also exerts a direct effect on prostate epithelium and cancer cells that upregulates expression of the cyclin-dependent kinase inhibitor p21. 412, 421, 423 Recent evidence suggests that IGFBP-3 activates epithelial TGF-β receptors [35] [36] [37] [38] ; as is well known, the antiproliferative effects of TGF-β are mediated by induction of p21 and other cyclindependent kinase inhibitors. 424, 425 Calcitriol may also increase production of TGF-β. 426 The effects of calcitriol on cell growth appear to be exerted primarily at the level of proliferation, rather than apoptosis. 427 However, calcitriol-mediated downregulation of certain antiapoptotic proteins, including bcl-2 and bcl-xL, has been reported in some studies. 411 Calcitriol has also been observed to reduce the invasiveness of certain prostate cancer cell lines 409 and can decrease production of parathyroid hormone-related peptide, 428, 429 which, as noted above, is an autocrine growth factor for prostate cancer and also has osteolytic activity.
IGFBP-3 is produced constitutively by healthy prostate epithelium; its production is substantially downregulated in most prostate cancers. [430] [431] [432] [433] Thus, upregulating production of this protective factor with calcitriol (or analogs thereof) may be viewed as a compensatory measure, reversing a shift in prostate cancer differentiation that promotes malignancy.
The fact that prostate cancers have minimal if any 1α-hydroxylase activity implies that sunlight or vitamin D supplementation are unlikely to influence prostate cancer (unless toxic doses of vitamin D are used). Pilot studies have evaluated the impact of calcitriol or its precursor 1α-hydroxycholecalciferol in prostate cancer patients. [434] [435] [436] [437] [438] Doses must be adjusted carefully and dietary calcium minimized to avoid induction of excessive hypercalcemia. A simple regimen that has proved to be well tolerated and that raises serum calcitriol levels to the range that is therapeutic in vitro (~1 nM) is 0.5 mg/kg once weekly. A minority of patients achieve a reduction in PSA with such regimens; the more common response has been a worthwhile reduction in PSA doubling time. Since calcitriol has relatively little impact on apoptosis, it is likely to be only palliative unless used in conjunction with cytotoxic or signal-modulating agents that upregulate apoptosis. In this regard, calcitriol has been reported to potentiate response to the cytotoxic agent docetaxel, as well as to radiotherapy. 439, 440 Estrogen Receptor-β Estrogens have been used in prostate cancer treatment as a strategy for indirectly suppressing gonadal testosterone production. However, normal prostate epithelium and, to a varying extent, prostate cancers express the β isoform of the estrogen receptor (ER-β). Thus, it is conceivable that estrogens or estrogen antagonists could have some direct impact on the induction or progression of prostate cancer. 441, 442 ER-β expression tends to be decreased in androgenindependent prostate cancer cell lines, owing to methylation of the ER-β promoter. 443, 444 Histological studies also report reduced ER-β expression in many recurrent prostate cancers. 444, 445 However, ER-β expression has been noted in most metastatic lesions. 446 The tendency of ER-β expression to diminish as prostate cancers mature has prompted the suggestion that this receptor may have a suppressor function in the prostate. 447 Indeed, prostate hyperplasia is commonly seen in aging ER-β-knockout mice. 448, 449 Transfection of DU-145 cells with the ER-β gene reduces the proliferation and invasiveness of these cells while increasing apoptosis; remarkably, these effects are seen in the absence of exogenous ligand. 447 ER-β transfection likewise slows proliferation in a human breast cancer cell line 450 ; the reported effects on expression of cyclins, cdk inhibitors, and c-myc are opposite to those of NF-κB. (In some cells, estrogen receptors and NF-κB have mutually antagonistic activity owing to competition for scarce coactivators 451, 452 : could this be true in prostate epithelium as well? If so, then loss of ER-β expression could contribute to the NF-κB upregulation typical of androgen-independent prostate cancer.)
Tamoxifen and the pure estrogen antagonist ICI-182,780 reduce the growth of both PC-3 and DU145 cells in vitro; coadministration of antisense oligodeoxynucleotides targeting ER-β reverses this effect. 453 The selective estrogen response modulator raloxifene, an antagonist for ER-β, has been shown to induce apoptosis in LNCaP, PC-3, PC-3M, and DU145 cell lines. 454, 455 Surprisingly, there do not appear to be any published studies examining the impact of these estrogen agonists/antagonists on growth of human prostate cancer xenografts in animals.
Genistein, suspected to be a chemopreventive agent for prostate cancer, has estrogen agonist activity that is relatively selective for ER-β. 456 In concentrations as low as 100 nM-sufficient to activate ER-β-free genistein achieves a modest but statistically significant reduction in the expression of androgen receptors in LNCaP cells, an effect inhibited by coadministration of a pure estrogen antagonist. 457 As anticipated, a corresponding reduction in PSA secretion was noted in genistein-treated cells. Since plasma concentrations of free genistein as high as 170 nM can be achieved when supranutritional doses (eg, 8 mg/kg) of genistein are administered orally to humans, 458 these observations may be relevant to the therapeutic and preventive potential of high-dose soy isoflavones. Although genistein has been shown to exert a wide range of antiproliferative effects on prostate cancer cells in vitro, including tyrosine kinase inhibition, grossly supraphysiological concentrations of free genistein in the micromolar range are usually required to elicit these; in contrast, the impact of genistein on ER-β function may be of physiological interest and conceivably is relevant to the favorable effects of oral genistein reported in prostate cancer xenograft models as well as in initial clinical trials. [459] [460] [461] [462] 
Peroxisome Proliferator-Activated Receptor-γ
Another nuclear receptor that may influence prostate cancer growth is peroxisome proliferator-activated receptor-γ (PPAR-γ). Activation of this receptor with various ligands has promoted apoptosis in several types of cancer. Recent studies show that most prostate cancers express this receptor. [463] [464] [465] [466] Ligands for this receptor have been reported to induce cell death or slow proliferation in the LNCaP, DU145, and PC-3 human prostate cancer cell lines 463, 464 ; the molecular biology responsible for this effect has not been defined. No published studies to date have examined the impact of pharmaceutical PPAR-γ agonists (such as thiazolidinediones) on prostate cancer xenografts in vivo. Nonetheless, the possibility that PPAR-γ agonists might have a clinical impact on prostate cancer is intriguing and merits further examination.
Potential Therapies in Search of a Target
Epidemiology, and/or rodent studies, and in a few instances pilot clinical trials, suggest that various nutrients and phytochemicals may have the potential to aid prevention or promote control of prostate cancer. These agents include lycopene, green tea polyphenols, [488] [489] [490] [491] [492] [493] [494] grape seed extract, 495 genistein, [459] [460] [461] [462] [496] [497] [498] [499] [500] [501] [502] [503] silibinin, 128, 129, 504 boron, 134 inositol hexaphosphate, 505 and omega-3-rich fish oils. Although putative biochemical targets for many of these agents have been defined in cell culture studies (most of these compounds have the potential to downregulate NF-κB, for example), the tendency of researchers to use supraphysiological concentrations in such studies renders their conclusions questionable. Nonetheless, inasmuch as these agents clearly are not cytotoxic-at least in the moderate concentrations that could be achieved in vivo-any genuine cancerostatic activity they possess is likely to reflect signal modulation. Thus, while it would be illuminating and potentially helpful to know the key targets of these agents in physiological concentrations, it could still be appropriate to include these agents in multifocal signaling modulation regimens even if their targets remain obscure.
Several recent epidemiological studies-though not all 506, 507 -suggest that people who consume seafood regularly are at decidedly lower risk for prostate cancers than are those who consume seafood infrequently. [508] [509] [510] [511] Furthermore, a diet high in fish oil (and relatively low though adequate in omega-6 oils) slows the growth of DU145 xenografts in nude mice. 512 In the context of a low-fat diet, 3 months of fish oil supplementation has been found to achieve significant increases of omega-3/omega-6 ratio in the plasma and gluteal fat of untreated prostate cancer patients; prostate cox-2 expression declined in the majority of these subjects. 513 By competing with arachidonic acid for incorporation into membrane phospholipids or at the active sites of cyclooxygenases and lipoxygenases, EPA/DHA have the potential to decrease production of certain arachidonate products (eg, PGE2 and 5-(S)-HETE) that encourage induction and growth of prostate cancer. Hopefully, future research will explore these possibilities. Fish oil omega-3s may also exert an angiostatic action on vascular endothelium [514] [515] [516] [517] [518] ; in particular, EPA and DHA are reported to decrease endothelial expression of the VEGF receptor flk-1 (KDR). 516, 518 Perhaps this plays some role in the quite general cancer-retardant activity of fish oil-rich diets in rodent studies. 519 
Toward Development of MSMTs
A rational and straightforward strategy for developing multifocal signal modulation therapies for prostate cancer can be proposed: 1 . Identify a group of agents to be tested. 2. Assess the plasma concentrations of these agents that can be achieved through tolerable and feasible oral dosing schedules in humans. It is crucial to determine the concentration of the free, unmetabolized agent. For example, the bulk of circulating plasma polyphenols are present as soluble conjugates that have limited intracellular penetrance; curcumin is rapidly hydrogenated to a less active form as it transits the human intestinal mucosa. 520 For some potential agents, such as antisense oligonucleotides, intravenous infusion during episodic treatment sessions may be the preferred mode of administration. 3. Examine the impact of combinations of these agents, in physiologically realistic concentrations, on proliferation, apoptosis, and proangiogenic capacity of several human prostate cancer cell lines in vitro. Presumably, combinations that address multiple prooncogenic signaling pathways will be more effective than those that focus on a single pathway. 4. After identifying combinations that have an additive or synergistic impact on several cell lines in vitro, test these combinations in human prostate cancer xenografts implanted in nude mice. 5. Once regimens have been established that are effective and seemingly well tolerated in xenograft models, and it has become ethically and legally appropriate to administer the component agents to patients, pilot clinical studies with these regimens can commence.
Concluding Thoughts
Ideally, multifocal signal modulation therapies that are optimally planned and executed should be able to lower the cancer proliferation rate and raise the spontaneous apoptosis rate, to such an extent that the latter equals or exceeds the former, resulting in tumor stasis or even objective remission. Realistically, though, the best that such strategies will achieve in some cases will be a slowing of tumor growth and spread. In such cases, combining signal modulation therapies with cytotoxic measures-drugs or radiotherapy-may enable more definitive therapeutic benefit to be achieved. It is reasonable to expect that signalmodulating measures that upregulate the machinery of apoptosis will potentiate the therapeutic response to certain cytotoxic measures. On the other hand, the downregulatory impact of signal modulation on proliferation rate may influence response to cytotoxins whose efficacy is cell-cycle specific. It is also crucial to consider the impact of signal modulation on the doselimiting side effects of cytotoxic therapy. Thus, the net impact of signal modulation on response to cytotoxic therapy may be complex and must be evaluated empirically. Tortora and colleagues have recently summarized evidence that signal-modulation therapies can often potentiate response to cytotoxic measures. 374 They have also conducted a series of studies evaluating the interaction between Iressa and a wide range of cytotoxic agents in human ovarian, breast, and colon cancer cell lines and in a colon cancer xenograft model. 521 The cell lines chosen for these studies all expressed EGFR as well as autocrine TGF-α (like most advanced prostate cancers) and thus experienced EGFR-driven proliferation. Despite the fact that a diverse range of chemotherapeutic drugs was tested (platinum-based agents, topoisomerase inhibitors, taxanes, and a thymidylate synthetase inhibitor), in virtually every study, Iressa was found to greatly potentiate the apoptotic response to cytotoxins. In the colon cancer xenograft model, concurrent administration of Iressa markedly prolonged survival of mice treated with topotecan, raltitrexed, or paclitaxel. Evidently, these findings bode well for the future of mixed cytotoxic/signal-modulating therapies. On the other hand, there is a report that antisense antagonism of EGFR can decrease the responsiveness of a human breast cancer cell line to cisplatin. 522 The timing of administration of the various agents might have an impact on therapeutic outcome. 523 Broad generalizations regarding the interaction of cytotoxic and signalmodulating therapies appear to be unwarranted at this time. Nonetheless, it is reasonable to anticipate that preclinical and clinical experience will eventually identify specific regimens of this type that will prove to be highly efficacious.
Suppression of tumor-evoked angiogenesis is now receiving prominent research attention as a strategy for cancer control. Many if not most of the signalmodulating measures discussed above have the potential to downregulate tumor production of various angiogenic factors. However, angiostatic therapies can also directly target endothelial function. Thus, it should be noted that several of the measures described here can decrease the responsiveness of endothelial cells to angiogenic factors 139 ; these include IGF-I downregulation, [524] [525] [526] [527] copper depletion, 528, 529 Hsp90 inhibition, 184 12LPO inhibition, 276, 278 AT-1 blockers, [530] [531] [532] c-Src inhibition, 247, 339, 533 green tea polyphenols, [534] [535] [536] [537] [538] [539] and fish oil. 516, 518, 540 Such measures are of particular interest in that their cancer-retardant efficacies may, at least in part, be independent of the metabolic peculiarities of the tumor.
The key point of this discussion is that significant, perhaps substantial progress in clinical treatment of prostate cancer need not be contingent on future "magic bullet" breakthroughs that may or may not ever arrive; the tools may be available now for therapies that are reasonably well tolerated and that can achieve a very worthwhile extension of functional life span in patients whose prostate cancer has escaped local control. What is needed are diligent and focused research efforts by laboratories and clinics that are more motivated to develop effective therapies than to generate profits from a specific patented drug. Doubtless there are additional molecular targets in prostate cancer, not touched on here, that could be profitably addressed; there can be no pretense that this discussion has been comprehensive. The chief purpose of this article has been to set forth the concept of "multifocal signal modulation therapy"-a concept that has emerged previously in the work of other creative researchers-and to provide some provisional insights and suggestions into how this strategy might be implemented with respect to clinical prostate cancer. Evidently, analogous analyses could be made for other prominent cancers whose molecular biology has already received considerable study. Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer. Anti-proliferative and apoptotic effects of anandamide in
